Advancements in medical science continue to reshape how society addresses substance use disorders, and among the most pivotal contributors to this transformation is addiction medicine. Bridging neurobiology, clinical care, and behavioral interventions, it provides a comprehensive framework for managing complex addiction profiles. Healthcare professionals are increasingly relying on this specialized field to offer evidence-based treatments tailored to individual needs, whether through pharmacologic strategies, motivational enhancement, or harm-reduction models. As challenges like opioid dependency and stimulant misuse evolve, the role of addiction medicine grows more essential in both urban hospitals and rural clinics. Ongoing research also supports integrating mental health assessments and comorbidity management to improve patient outcomes. Specialists in this area frequently collaborate across disciplines, working with psychiatrists, social workers, and public health officials to shape effective policies and therapeutic pathways. By refining diagnostic tools and introducing more precise treatment modalities, addiction medicine continues to drive meaningful recovery and long-term stabilization.
Title : Tailoring biblio-poetry therapies using AI and biofeedback for addiction treatment
Nile Stanley, University of North Florida, United States
Title : The A-B-C of happiness coaching
Alphonsus Obayuwana, Triple-H Project LLC, United States
Title : Clinical pharmacology of marijuana: Update 2024
Frederick J Goldstein, Philadelphia College of Osteopathic Medicine, United States
Title : Trait-based recovery: Evidence-based trait activation to reduce depression, anxiety, and improve client engagement in addiction treatment
Jason Glenn Roop, The Center for Trait-Based Transformation, United States
Title : An investigation of the factors responsible for ubstance abuse from a cognitive perspective based on a mixed method approach
Adewole Olukorede, Literary Edifice, Italy
Title : A Long-Acting Naltrexone Implant (for Opioid Use Disorder: First-in-Human Phase I Trial)
Steven M Cohen, Akyso Therapeutics, United States